The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
Subscribe To Our Newsletter & Stay Updated
